Startup profile · funding coverage
Maze Therapeutics
Clinical-stage biotech using human genetics to develop precision small-molecule medicines.
Stage
growth
Status
private
Coverage
full
Why Maze Therapeutics is interesting
Maze's Compass platform links genetic variants to druggable pathways — a16z joined ARCH and Third Rock as co-investors across $496M+ raised toward renal, cardio, and metabolic programs.
Key facts
- Series D (Dec 2024): $115M co-led by Frazier Life Sciences and Deep Track; a16z, ARCH, Third Rock, General Catalyst among existing investors (company IR)
- Series A (Feb 2019): $191M with ARCH, Third Rock, GV (company IR)
- Co-investors: ARCH, Third Rock, General Catalyst added; Frazier/Deep Track not in VCT directory (sources reviewed 2026-07-24)
Investors in our directory
Funds linked from Maze Therapeutics's profile — open a fund page for stage focus and related deal articles.
Industries
Biotech & Life Sciences Healthtech
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Maze Therapeutics's financing or category context.
Last updated: 2026-07-24